<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248585</url>
  </required_header>
  <id_info>
    <org_study_id>SC23</org_study_id>
    <nct_id>NCT01248585</nct_id>
  </id_info>
  <brief_title>Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases</brief_title>
  <official_title>A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done because is is not known if dexamethasone can prevent pain flare&#xD;
      (their pain temporarily gets worse before it gets better) caused by the radiation used to&#xD;
      treat painful bone metastases. Using dexamethasone to prevent pain like this has been studied&#xD;
      in a few people and seems promising, but it is not clear if it can decrease the pain or&#xD;
      prevent the pain flare before it happens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous research has shown that for patients who receive radiation therapy to treat their&#xD;
      painful bone metastases, about 2 out of every 5 patients (about 40%) experience pain flare.&#xD;
      The purpose of this study is to find out whether pain flare is prevented by receiving 8mg&#xD;
      dexamethasone at least one hour prior to radiotherapy and once daily for the following 4&#xD;
      days. To do this, half of the patients in this study will get dexamethasone and the other&#xD;
      half will receive a placebo (a substance that does not do anything). Using a placebo is the&#xD;
      best way to see if a new therapy is effective and to clearly see the potential side effects&#xD;
      and impact on quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2010</start_date>
  <completion_date type="Actual">November 27, 2015</completion_date>
  <primary_completion_date type="Actual">May 25, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation-induced Pain Flare Incidence</measure>
    <time_frame>10 days</time_frame>
    <description>The incidences of radiation-induced pain flare from the time of radiotherapy treatment to ten days after the completion of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation-induced Pain Flare Incidence From Day 6 to Day 10 After Radiotherapy Treatment</measure>
    <time_frame>From Day 6 to day 10 after radiotherapy treatment</time_frame>
    <description>Reduction in incidence of radiation-induced pain flare from Day 6 to Day 10 after radiotherapy treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Use</measure>
    <time_frame>10 days</time_frame>
    <description>Change in mean analgesic use from baseline to day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Radiation Treatment at Six Weeks</measure>
    <time_frame>From day 0 to 6 weeks</time_frame>
    <description>Response to radiation treatment at six weeks after treatment. Complete response (CR) is defined as a worst pain score of zero (0) at the bony metastatic site with no concomitant increase in analgesic intake (stable or reduced oral morphine equivalent dosage (OMED)).&#xD;
Partial response (PR) is defined as any of the following:&#xD;
i. Reduction in worst pain score of two or more at the bony metastatic site on a 0-10 scale without analgesic increase.&#xD;
ii. Analgesic reduction of 25% or more from baseline without an increase in worst pain score with reference to baseline.&#xD;
iii. For patients who were using opioid analgesics at the baseline assessment, a daily oral morphine equivalence of zero (0) without an increase in worst pain score relative to the baseline worst pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Intensity Score Over 10 Days After Radiotherapy.</measure>
    <time_frame>Pain intensity score change from baseline of day 0 to day 10 after radiation</time_frame>
    <description>Change in pain score over 10 days after radiotherapy, pain score range from 0 (no pain) to 10 (worst pain as can imagine).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo tablets taken once daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo tablets taken once daily for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a histologically or cytologically proven malignancy. All non-hematologic&#xD;
             malignant tumours of any histology are eligible.&#xD;
&#xD;
          -  Be 18 years of age or older at the time of randomization.&#xD;
&#xD;
          -  Have bone metastasis(es) corresponding to the clinically painful area(s) documented by&#xD;
             radiological imaging within six months prior to randomization.&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) must be ≥ 40 at the time of the baseline evaluation&#xD;
             (within seven days prior to randomization). As it is difficult to obtain complete data&#xD;
             from inpatients on a daily basis, they should not be randomized to this study.&#xD;
&#xD;
          -  Is planned to receive palliative radiotherapy to one or two bony metastasis(es) with&#xD;
             the treatment given as 8 Gy in a single fraction to all sites to be followed for the&#xD;
             study. Although a maximum of two sites can be treated and followed for the study,&#xD;
             patients with more than two skeletal metastases are eligible. At the time of delivery&#xD;
             of study radiotherapy, only the site(s) being followed for the study may be treated.&#xD;
&#xD;
          -  Is able to provide the worst pain score at the bony metastatic site(s) planned for&#xD;
             palliative radiotherapy.&#xD;
&#xD;
          -  Has a baseline worst pain score ≥ 2 on a scale of 0-10 at all the bony metastatic&#xD;
             site(s) planned for palliative radiotherapy as part of this study within 7 days prior&#xD;
             to randomization. If two painful sites will be followed for the study, this&#xD;
             requirement must be met on the same day for both sites.&#xD;
&#xD;
          -  Is able and willing to fill out the daily diary.&#xD;
&#xD;
          -  Is able (i.e. sufficiently fluent) and willing to complete the quality of life&#xD;
             questionnaire in either English or French. The baseline assessment must be completed&#xD;
             within required timelines prior to randomization. Inability (illiteracy in English or&#xD;
             French, loss of sight, or other equivalent reason) to complete the questionnaires will&#xD;
             not make the patient ineligible for the study. However, ability but unwillingness to&#xD;
             complete the questionnaires will make the patient ineligible.&#xD;
&#xD;
          -  Patient consent must be obtained according to local Institutional and/or University&#xD;
             Human Experimentation Committee requirements. It will be the responsibility of the&#xD;
             local participating investigators to obtain the necessary local clearance, and to&#xD;
             indicate in writing to the NCIC CTG Study Coordinator that such clearance has been&#xD;
             obtained, before the trial can commence in that centre. Because of differing&#xD;
             requirements, a standard consent form for the trial will not be provided but a sample&#xD;
             form is provided. A copy of the initial full board REB approval and approved consent&#xD;
             form must be sent to the central office. The patient must sign the consent form prior&#xD;
             to randomization. Please note that the consent form for this study must contain a&#xD;
             statement which gives permission for the NCIC CTG and monitoring agencies to review&#xD;
             patient records.&#xD;
&#xD;
          -  If being enrolled through a centre participating in the correlative science component&#xD;
             of the study, is willing and able to provide a pre- and post-treatment urine sample.&#xD;
             Language pertaining to patient consent for urine collection must be included in the&#xD;
             consent form for the main study at these centres. The patient must sign this consent&#xD;
             form prior to collection of the first urine sample.&#xD;
&#xD;
          -  If being enrolled through a centre participating in the correlative science component&#xD;
             of the study, patient consent for the saliva collection component of the trial must be&#xD;
             obtained in the same manner as outlined above for the main study consent. The patient&#xD;
             must sign the saliva collection Informed Consent form.&#xD;
&#xD;
          -  Must be accessible for treatment and follow-up. Investigators must be reasonably&#xD;
             assured that the patients randomized on this trial will be available for complete&#xD;
             documentation of the treatment, adverse events, and follow-up.&#xD;
&#xD;
          -  Protocol treatment is to begin within one week of patient randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic malignancies (leukemia, Hodgkin's or non-Hodgkin's lymphoma&#xD;
             or plasma cell dyscrasia, including multiple myeloma) are ineligible as steroids&#xD;
             constitute anti-cancer therapy for these malignancies.&#xD;
&#xD;
          -  Concurrent use or use within previous seven days of any corticosteroid medication&#xD;
             other than topical or inhaled preparations. Patients with any type of cancer who are&#xD;
             receiving steroids as a component of their systemic therapy are ineligible. Patients&#xD;
             requiring steroids for a co-existing medical problem are ineligible. Patients who&#xD;
             received a one- to three-day dose of steroids as an antiemetic for chemotherapy&#xD;
             treatment are eligible, as long as at least 72 hours have elapsed since the last dose&#xD;
             of antiemetic therapy.&#xD;
&#xD;
          -  Medical contraindications to corticosteroids such as uncontrolled diabetes mellitus,&#xD;
             uncontrolled hypertension, active peptic ulcer or hypokalemia.&#xD;
&#xD;
          -  Uncorrected hypokalemia that is known to exist within 7 days prior to randomization.&#xD;
             Patients with previous hypokalemia that has been corrected are eligible. Hypokalemia&#xD;
             is defined as a potassium level &lt; 3.0 mmol/L. Testing of electrolytes, including&#xD;
             potassium level, is not a protocol requirement.&#xD;
&#xD;
          -  Random glucose level ≥ 13.9 mmol/L within 7 days prior to randomization.Testing of&#xD;
             glucose within 7 days prior to randomization is a protocol requirement. Point of care&#xD;
             testing with a glucometer is permissible.&#xD;
&#xD;
          -  Pathological fracture of the femora, tibiae, fibulae, humeri, radii or ulnae at the&#xD;
             site(s) to be followed for the study.&#xD;
&#xD;
          -  Radiological evidence of high-risk lesions for pathological fractures in the femora,&#xD;
             tibiae, fibulae, humeri, radii or ulnae at the site(s) to be followed for the study&#xD;
             (lytic lesions &gt; 3 cm or &gt; 50% cortical erosion of bone diameter).&#xD;
&#xD;
          -  Clinical or available radiologic evidence of spinal cord or cauda equina compression&#xD;
             at the site(s) to be followed for the study.&#xD;
&#xD;
          -  Plans to receive palliative radiotherapy to a site or sites other than the one(s)&#xD;
             being followed for the study during the ten-day period following study radiotherapy.&#xD;
&#xD;
          -  Planned orthopedic intervention, including kyphoplasty, vertebroplasty or&#xD;
             cementoplasty, to any of the site(s) to be followed for the study.&#xD;
&#xD;
          -  Prior palliative surgery to any of the site(s) to be followed for the study.&#xD;
&#xD;
          -  Inability, with available translator assistance, to record pain score and medication&#xD;
             consumption in the daily diary and to communicate this to study personnel.&#xD;
&#xD;
          -  Receipt of radiopharmaceutical treatment at any time.&#xD;
&#xD;
          -  Previous external beam radiotherapy (including hemibody radiotherapy) using a field&#xD;
             that included the site(s) to be followed for the study.&#xD;
&#xD;
          -  Inability to swallow or tolerate oral medications, e.g. due to intractable nausea&#xD;
             and/or emesis.&#xD;
&#xD;
          -  Plans to receive cytotoxic chemotherapy or systemic steroids during the on-study&#xD;
             period (day of study radiotherapy and the subsequent ten days).&#xD;
&#xD;
          -  Plans to start or stop systemic therapy other than cytotoxic chemotherapy (e.g.&#xD;
             hormonal therapy; immunotherapy; bisphosphonates) during the on-study period (day of&#xD;
             study radiotherapy and the subsequent ten days). Patients who are already receiving&#xD;
             these types of treatments are eligible as long as no changes are planned during the&#xD;
             study period.&#xD;
&#xD;
          -  Regular use of a non-steroidal anti-inflammatory drug (NSAID). Patients must not be&#xD;
             taking NSAIDs at randomization and their use during the on-study period (day of study&#xD;
             radiotherapy and the subsequent ten days) must not be required or expected. Patients&#xD;
             who use daily low-dose ASA for anti-platelet therapy are eligible if ASA has been used&#xD;
             for more than one month prior to the time of randomization.&#xD;
&#xD;
          -  Plans for a change in analgesic regimen on the day of randomization.&#xD;
&#xD;
          -  Previous entry on the SC.23 study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward LW Chow</last_name>
    <role>Study Chair</role>
    <affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto ON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlo De Angelis</last_name>
    <role>Study Chair</role>
    <affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto ON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alysa Fairchild</last_name>
    <role>Study Chair</role>
    <affiliation>Cross Cancer Institute, Edmonton AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Abbotsford Centre</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2S 0C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vitalite Health Network - Dr. Leon Richard</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Health Centre at Southlake</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, Brundage M, DeAngelis C, Wong RKS. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Nov;16(15):1463-1472. doi: 10.1016/S1470-2045(15)00199-0. Epub 2015 Oct 18.</citation>
    <PMID>26489389</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>July 4, 2016</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptom Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone</title>
          <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT</population>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone</title>
          <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="298"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.6" spread="12.9"/>
                    <measurement group_id="B2" value="68.6" spread="12"/>
                    <measurement group_id="B3" value="67.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary cancer site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of painful sites</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiation-induced Pain Flare Incidence</title>
        <description>The incidences of radiation-induced pain flare from the time of radiotherapy treatment to ten days after the completion of treatment</description>
        <time_frame>10 days</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation-induced Pain Flare Incidence</title>
          <description>The incidences of radiation-induced pain flare from the time of radiotherapy treatment to ten days after the completion of treatment</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided 0.05 level test with 90% power, 298 participants required.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>1-sided p-value.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiation-induced Pain Flare Incidence From Day 6 to Day 10 After Radiotherapy Treatment</title>
        <description>Reduction in incidence of radiation-induced pain flare from Day 6 to Day 10 after radiotherapy treatment</description>
        <time_frame>From Day 6 to day 10 after radiotherapy treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation-induced Pain Flare Incidence From Day 6 to Day 10 After Radiotherapy Treatment</title>
          <description>Reduction in incidence of radiation-induced pain flare from Day 6 to Day 10 after radiotherapy treatment</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.432</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Use</title>
        <description>Change in mean analgesic use from baseline to day 10.</description>
        <time_frame>10 days</time_frame>
        <population>Patients with baseline and day 10 Analgesic Use data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Use</title>
          <description>Change in mean analgesic use from baseline to day 10.</description>
          <population>Patients with baseline and day 10 Analgesic Use data.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="36.0"/>
                    <measurement group_id="O2" value="9.83" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Radiation Treatment at Six Weeks</title>
        <description>Response to radiation treatment at six weeks after treatment. Complete response (CR) is defined as a worst pain score of zero (0) at the bony metastatic site with no concomitant increase in analgesic intake (stable or reduced oral morphine equivalent dosage (OMED)).&#xD;
Partial response (PR) is defined as any of the following:&#xD;
i. Reduction in worst pain score of two or more at the bony metastatic site on a 0-10 scale without analgesic increase.&#xD;
ii. Analgesic reduction of 25% or more from baseline without an increase in worst pain score with reference to baseline.&#xD;
iii. For patients who were using opioid analgesics at the baseline assessment, a daily oral morphine equivalence of zero (0) without an increase in worst pain score relative to the baseline worst pain score</description>
        <time_frame>From day 0 to 6 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Radiation Treatment at Six Weeks</title>
          <description>Response to radiation treatment at six weeks after treatment. Complete response (CR) is defined as a worst pain score of zero (0) at the bony metastatic site with no concomitant increase in analgesic intake (stable or reduced oral morphine equivalent dosage (OMED)).&#xD;
Partial response (PR) is defined as any of the following:&#xD;
i. Reduction in worst pain score of two or more at the bony metastatic site on a 0-10 scale without analgesic increase.&#xD;
ii. Analgesic reduction of 25% or more from baseline without an increase in worst pain score with reference to baseline.&#xD;
iii. For patients who were using opioid analgesics at the baseline assessment, a daily oral morphine equivalence of zero (0) without an increase in worst pain score relative to the baseline worst pain score</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>Fisher exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Intensity Score Over 10 Days After Radiotherapy.</title>
        <description>Change in pain score over 10 days after radiotherapy, pain score range from 0 (no pain) to 10 (worst pain as can imagine).</description>
        <time_frame>Pain intensity score change from baseline of day 0 to day 10 after radiation</time_frame>
        <population>Patients with baseline and day 10 pain evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Intensity Score Over 10 Days After Radiotherapy.</title>
          <description>Change in pain score over 10 days after radiotherapy, pain score range from 0 (no pain) to 10 (worst pain as can imagine).</description>
          <population>Patients with baseline and day 10 pain evaluation.</population>
          <units>units on pain intensity scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="2.88"/>
                    <measurement group_id="O2" value="-1.99" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.06</ci_lower_limit>
            <ci_upper_limit>3.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0 to 6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone</title>
          <description>2 x 4 mg dexamethasone tablets taken once daily for 5 days&#xD;
Dexamethasone: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 placebo tablets taken once daily for 5 days&#xD;
Placebo: 2 placebo tablets taken once daily for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE V4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keyue Ding, Biostatistician</name_or_title>
      <organization>Canadian Cancer Trials Group</organization>
      <phone>613-533-6430</phone>
      <email>kding@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

